Opinion of the Transparency Council – posaconazolum

At its meeting on May 16, 2022. The Transparency Council adopted Opinion No. 77/2022 on the inclusion in reimbursement of medicines containing the active substance posaconazolum within the scope of indications for use or dosage or route of administration different from those specified in the Summary of Product Characteristics.

Publication with the minutes of the Transparency Council meeting